respiratory Flashcards
coagulase pos vs neg bacteria
Coagulase positive
- S.aureus
Coagulase negative
- Coagulase Negative Staphylococcus (CNS)
staph aureus (including MRSA)
coag-pos
many virulent factors
causes
- infections from boils to osteomyelitis
- blood-stream infections
- toxin illnesses
staphlococci
coag-neg
not as virulent
Lots of different species
infections in the presence of foreign body (e.g prosthetic joint).
Staph saprophyticus: cause of UTI
streptococcus
alpha haemolytic - green zone
eg - Str. pneumoniae
beta haemolytic - golden yellow zone
eg - Str. Pyogenes
Dalton’s law
gases in a mixture exert pressures that are independent of each other
Henry’s Law
the concentration of a dissolved gas is directly proportional to its partial pressure
oxygenated blood
Po2 = 13.3kPa [O2] = 200ml/L = 8.9mmol/L
1.5% is dissolved in plasma and 98.5% bound to haemoglobin
modulation of oxygen binding to haemoglobin
The bohr effect - H+/ph
the haldane effect - PCO2 reactignwith amino groups in deoxy-Hb > carbino-Hb (this has a lower O2 affinity)
binding of 2,3-bisphospoglycerate
2,3-bisphospoglycerate
present only in ethrocytes
conc - 4mmol/L
preferably binds to deoxy-Hb, 1 mol 2,3-BPG per Hb tetramer
lowers affinity of O2 to improve O2 delivery
foetal Hb has a lower affinity for it
effects of anaemia and CO poisoning
CO is a shorter curved shape
anaemia is a shorter S-shaped curve
dissolved Carbon Dioxide
PCO2 = 5.3 kPa [CO2] = 530 ml/L = 24 mmol/L
Of this,
7% is dissolved CO2
70% is hydrated to carbonic acid and bicarbonate
23% is combined as carbamino-haemoglobin
gas exchange in the alveoli
Gas exchange in the alveoli is so rapid that equilibrium is usually attained. If equilibrium is not reached, it is usually because of V/Q mismatch.
hypoxia more likely than hypercapnia as CO2 diffusion is 20x faster than O2
nitrogen
Elemental nitrogen (N2) has no function in human metabolism. Its solubility in blood is low, at high pressure dissolves in blood and tissues, producing nitrogen narcosis (‘rapture of the deep’); return to normal pressure nitrogen emboli may form in capillaries - local ischaemia, bubbles within tissues (‘bends’).
haemaglobin structure
tetrameric protein with two types of subunit
molecular weight 64,500
HbA (normal adult) = a2b2 ; HbF (foetal) = a2y2
bicarbonate
carbonic anhydrase catalyses hydration of CO2 to carbonic acid
carbonic acid ionixes to bicarbonate
bicarbonate moves into plasma in exchange for CL- - THE “CHLORIDE SHIFT”
most CO2 is transported as bicarbonate in plasma
acetazolamide
inhibits carbonic anhydrase
used to be used as a diuretic (inhibits Na+ uptake in kidney)
now used to prevent altitude sickness - lowering ph of blood
elastic recoil definition
having the property of returning to the original shape after being distorted
to spring back
expiration - resting breath -
inspiratory muscle activity ceases - elastic recoil causes lungs to shrink (passive)
elastic recoil causes positive pressure in alveoli - air moves out towards mouth
mechanism of inspiration
inspiratory neural activity from brain
diaphragm and external intercostals contract and thoracic cage expands
pleural pressure < atmospheric P
air flows down conc grad. into alveoli
expiration - large/forced breath
internal intercostals and abdominal muscles contract
diaphragm moves up, ribs are depressed - reduce thoracic volume
alveolar pressure increases and air flows out of alveoli
Vt
tidal volume
volume of gas breathed out with each breath (litres)
normally 0.4-0.8 litres
f r
respiratory frequency
breaths per minutes
normally 12-15 breaths/min
(V)
minute ventilation = Vt * f r
amount of gas breathed in or out of lungs per minute litres/min
normally 5-8 litres/min
central neural control for breathing
cortex + upper pons
- removal = slow gasping breaths
pons
- removal = return to rhythmic breathing
medulla
- removal stops breathing
spinal cord
respiratory groups in brainstem
pontine RG
ventral RG
dorsal RG
things that change the basic breathing pattern
inhaled noxious substances
speech
sleep
exercise
feedback inputs to the resp rhythm generator
lung receptors (afferent nerve fibres carried in vagus)
- slowly adapting rec
- rapidly adapting rec
- C-fibre endings
CHEMORECEPTORS
- central chemorec
- peripheral chemorec.
slowly adapting receptors (SARs)
- also called stretch rec.
- mechanorec. close to airway smooth muscle
- stimulated by stretch of airway walls in insp.
- help initiate exp. & prevent overinflation
- initiate Hering-Breuer inflation reflex
- afferent fibres = myelinated
rapidly adapting receptors (RARs)
- also called irritant receptors
- primarily mechanoreceptors responding to rapid lung inflation
- respond to chemicals (eg histamine, smoke…)
- RARa in trachea & large bronchus initiate cough, mucus prod. &
bronchoconstriction - afferent fibres = myelinated
C-fibre endings
- unmyelinated nerve fibres
- in broncus - stimulated ny increased interstitial fluid (oedema) & inflammatory mediators (histamine, prostagladins, bradykinins)
- pulmonary c-fibres
(JUSTAPULMONARY CAPILLARTY RECEPTOR)
response to O2 & CO2
chemoreceptors
-peripheral
fast response to ;
arterial pO2, arterial pCO2, arterial h+
-central slow response to ;
arterial pCO2
blood brain barrier
pCO2 can’t cross over so is converted into H+ which is picked up by central chemoreceptors on surface of medulla which generates a medullary rhythm
breathing during sleep
Respiratory drive decreases (loss of wakefulness drive)
– reduction in metabolic rate
– reduced input from higher centres such as pons and cortex
• Loss of tonic neural drive to upper airway muscles
phasic upper airway activity
contraction of upper airway muscles
opening of upper airway
facilitates inward airflow
tonic upper airway activity
continuous background activity
tends to maintain patent airway
varies with state of alertness
obstructive sleep apnoea (OSA)
Common
• Fragments sleep causing daytime sleepiness
• Important cause of traffic accidents
• Risk factors: obesity, alcohol, nasal obstruction, anatomical anomalies
respiratory depressant drugs
anaesthetics
- almost all
analgesics
- opioids (morphine and its analogues)
sedatives (anti-anxiolytics, sleeping tablets)
- benzodiazapines (diazepam, temazepan, etc)
respiratory stimulant drugs
Primary action:
Doxapram
Secondary action:
B 2 - agonists (bronchodilators)
generation of basic rhythm
- Discharge from the inspiratory neurones activates the respiratory muscles via spinal motor nerves, resulting in inspiration
- Expiratory neurones fire and inhibit the inspiratory neurones. Nerve impulses to the inspiratory muscles stop and passive expiration occurs.
- If forceful expiration is required, expiratory neurone activity also activates expiratory muscles to enhance expiration
lung defence mechansims
Mechanical
• Ciliated epithelium
• Mucus
• Cough
Immunological
• IgA & antimicrobials in mucus
• Resident alveolar macrophages & dendritic cells
• Innate / adaptive immune responses
what is the parenchyma
The parts of the lungs involved in gas transfer
including the alveoli, interstitium, blood vessels,
bronchi and bronchioles.
pneumonia
Greatest cause of deaths due to infection in the developed
world
• Eighth leading cause of death (2.3% of all deaths) in the United States
• 15% of all deaths of children under 5 yrs
• Caused by range of
pathogens • bacteria • viruses • fung
pneumonia categories
- Community acquired
- Hospital acquired
- Health care associated
- Aspiration associated
- Immunocompromised host
- Necrotising / abscess formation
community acquired pneumonia
Streptococcal pneumoniae • Haemophilus influenzae • Moraxella catarrhalis • Staphylococcus aureus • Klebsiella pneumoniae / Pseudomonas aeurginosa • Mycoplasma pneumoniae
hospital acquired / Healthcare associated pneumonia
- Gram-negative rods, Enterobacteriaceae, Pseudomonas
* Staphylococcus aureus (usually methicillin-resistant)
aspiration pneumonia
• Anaerobic oral flora mixed with aerobic bacteria
pneumonia in immunocompromised host
- Cytomegalovirus
- Pneumocystis jiroveci (PCP)
- Mycobacterium avium-intracellulare
- Invasive aspergillosis
- Invasive candidiasis
- “Usual” bacterial, viral, and fungal organisms
necrotising / abscess formation pneumonia
• Anaerobes, S. aureus, Klebsiella, S. pyogenes
respones to infection -neutrophils
Chemotaxis • Degranulation • Reactive oxygen species • Extracellular traps • Phagocytosis
response to infection - macrophages
Cytokine & chemokines • Phagocytosis (bacteria & dead cells) • Antimicrobial peptides • Resolution • Also involves T cells, dendritic cells & epithelial cells
clinical presentation of pneumonia
Cough • Sputum • Pyrexia • Pleuritic chest pain • Haemoptysis • Dyspnoea • Hypoxia
bronchopneumonia
Most common pattern • Patchy consolidated areas of acute suppurative inflammation • Often elderly with risk factors • Cancer, heart failure, renal failure, stroke, COPD
lobar pneumonia
Rust coloured sputum
• S. pneumoniae
• consolidation of a large portion of a
lobe or of an entire lobe
complications of pneumonia
Local • Abscess formation • Empyema Systemic • Sepsis • ARDS • Multi-organ failure Not resolving? • ?cancer
acute respiratory distress syndrome
- Incidence 10-14/100,000/yr
- Mortality rate ~40%
Clinical diagnosis
• Hypoxia (PaO2/FiO2 ≤ 300mmHg )
• Non-cardiogenic pulmonary oedema
Causes
• Direct – pneumonia, aspiration, hyperoxia, ventilation
• Indirect – sepsis, trauma, pancreatitis, acute hepatic
failure
bronchiectasis
Definition • The permanent dilatation of one or more large bronchi • Typically affects the 2nd to 8th order of segmental bronchi. • largest central airways more robust.
tuberculosis
- Extremely common worldwide
- 8.9 million new cases in 1995
- 1.66 million die per annum of this disease
- Much more common in developing world
Predisposing factors • Alcoholism • Diabetes mellitus • HIV / AIDS • Some ethnic groups
primary TB
3-4 weeks
- multiplies within alveolar macrophages (can’t kill)
- bacterium resides in phagasomes & carried lymph nodes -> circulation
3-8 weeks
- onset of cellular immunity & delayed hypersensitivity
- activated lymphocytes further activate macrophages to kill
- most primary infections arrested
- few bacilli may survive dormant
progressive primary TB
Infection not arrested
• Minority
• Infants, children, immunocompromised
Tuberculous bronchopneumonia
• Infection spreads via bronchi
• Results in diffuse bronchopneumonia
• Well developed granulomas do not form
Miliary Tuberculosis • Infection spreads via blood-stream • Organisms scanty • Multiple organs • lungs, liver, spleen, kidneys, meninges, brain
secondary tuberculosis
Also termed ‘Post-primary’ TB • Reactivation of old, often subclinical infection • Occurs in 5-10% of cases of primary infection • More damage due to hypersensitivity • Apical region of lung • Tubercles develop locally, enlarge and merge • Erode into bronchus and cavities develop • May progress to tuberculous bronchopneumonia
other causes of granulomatous pulmonary inflammation
Other infection – fungi • Sarcoidosis • Rheumatoid arthritis • Berrylosis • Hypersensitivity pneumonitis • Aspiration pneumonia • Langerhans Cell Histiocytosis
asbestoes
• Occupational lung disease • Exposure in shipyards, building trade • Several diseases • Pleural plaques (benign) • Asbestosis (progressive fibrosis) • Mesothelioma • Adenocarcinoma • Issues surrounding compensation for patient and families • Other occupational factors • Silica, coal dust, berrylium
hypersensitivity pneumonitis
• Type III hypersensitivity • Ab/Ag complex within the lung • Various causative agents - Farmer’s lung - Pigeon fancier’s lung - Mushroom picker’s lung - Hot tub lung (!) • Most resolve when agent of exposure removed but can be chronic
complications of bronchiectasis
Local • Distal airway damage / loss and lung fibrosis • Pneumonia • Pulmonary abscess formation • Haemoptysis • Airway colonisation by aspergillus • Aspergilloma • Tumourlet formation
Physiological
complications
• Respiratory failure
• Cor pulmonale
- Systemic complications
- Metastatic abscess
- Amyloid deposition
patterns of bronchiectasis
Based on imaging appearances • Cylindrical • Sacular • Varicose • Cystic
function of the chest wall
1st Respiration
2nd Protection
3rd Muscle Attachments
thoracic cavity
Divided into 3 major spaces
• Heart with coverings (pericardium - pericardial cavity) + the
major vessels
• Lungs with coverings (pleura - pleural cavities)
chest wall anatomy
• Thoracic vertebrae • Ribs • Sternum - manubrium, body, xiphoid process •Intercostal spaces - intercostal muscles
features of a thoracic vertebrae
- body
- facets for articulation with ribs
- facet for articulation with adjacent vertebra
- transverse, inferior, spinous, superior processes
- lamina
- pedicle
- vertebral foreamen
features of a rib
posterior -> anterior
- head
- neck
- tubercle
- angle
- internal surface
- costal groove
- external surface
- costal cartilage
sternocostal joints
true ribs - I-VII
false ribs - VIII-XII (articulate with sternum via costal cartilage of rib above)
floating ribs - XI-XII (the 2 at the bottom)
intercostal space
- external and internal and innermost intercostal muscles
- intercostal vein, artery and nerve
- collateral branches of V, A & N
diaphragm openings
Inferior Vena Cava - T8
caval opening
• Oesophagus - T10
esophageal hiatus
• Aorta - T12
aortic hiatus
trachea
c-shaped hyaline cartilage rings
bifurcates into R & L main bronchus at TIV/TV
Carina - hook-shaped tracheal ring
bronchial trees - L & R
Right main bronchus Wider Vertical Shorter Divides into 3
Left main bronchus Long More horizontal Thin Divides into 2
bronchial tree
Trachea Main bronchus (primary) Lobar bronchi (3R, 2L) (secomndary) Segmental bronchi (tertiary) Conducting bronchioles Respiratory bronchioles Alveoli Alveolar ducts Alveolar sacs
alveoli
- microscopic air cells
- 150-300 million in adults
- single layer epithelial & elastic fibres line the walls
- surrounded by capillary network
- coated with thin layer pulmonary surfactant to prevent collapse
lung lobes
right
- superior
- middle
- inferior
- oblique fissure
- horizontal fissure
left
- superior
- inferior
- oblique fissure
- lingula
right medial surface lung
root structures
- pulmonary arteries
- pulmonary veins
- bronchus
impressions
- superior vena cava
- inferior vena cava
- oesophagus
- azygos vein
hilum
where important structures enter / exit each lung
left medial surface lungs
smaller than right lung
root structure
- P. arteries
- P. veins
- bronchus
impressions
- heart
- aortic arch
- thoracic aorta
- oesophagus
- L. subclavian artery
lung development
During development the lung is pushed into the sac to form two layers:Visceral & Parietal pleura
costodiaphragmatic recess
Between costal pleura & diaphragmatic pleura
Clinically important
mediastinum
Separates the pleural cavities
Divided into two parts: - Superior mediastinum - Inferior mediastinum Anterior Middle Posterior
contents of mediastinum
Aorta Heart Azygous vein Trachea Main bronchi Oesophagus Vagus nerves Phrenic nerves Thoracic duct
innervation to pleura
Parietal pleura – somatic innervation
Costal pleura – intercostal nerves
Mediastinal pleura –
phrenic nerves
Diaphragmatic pleura
- phrenic nerves to domes
- Lower 5 intercostal nerves to periphery
Visceral pleura – autonomic innervation
innervation to mediastinum
Vagus nerve
Parasympathetic supply to all organs of thorax
Phrenic nerve
Motor & sensory to diaphragm
lungs - pleura
2 layers of pleura
parietal pleura
- costal
- mediastinal
- diaphragmatic
- cervical
visceral pleura
- adhere to wall of lungs
- covering surface of each lobe
therapeutic index
= toxic conc. / effective conc.
alexander fleming
- observed fungal exudate killing staphylococci (1928)
- unable to purify penicillin
- later purified by Florey and Chain
- 1st antibiotic in clinical use
- used against gram positive bacteria
pharmacokinetics
The time course of events relating to how the body
handles the drug
Includes absorption, distribution, metabolism,
protein-binding, excretion
Measured by:
volume of distribution, Cmax, tmax, T1/2 : half life
pharmacodynamics
Describes the interaction between the antibiotic
and the bacteria
Includes bacteriocidal/ bacteriostatic activity,
Minimum Inhibitory Concentration (MIC),
Minimum Bactericidal Concentration (MBC),
Post antibiotic effect
Time dependent killing
Concentration
dependent killing
antibiotic classification
1. Effect on micro organism - bacteriostatic, bactericidial (2. Chemical structure) 3. Target site - cell wall - cell membrane - protein synthesis - nucleic acid synthesis
cell wall synthesis inhibitirs
Earliest known antibiotics
• Still some of the safest antibiotics
• Selectively toxic to bacteria because there is no
cell-wall in mammalian cells
• Removal of cell-wall destroys bacterial
maintenance of osmotic pressure
• Usually bactericidal in action
cell wall synthesis inhibitors examples
beta-lactams
glycopeptides
eg vancomycin, teicoplanin
beta lactams
- penicillins
- cefalosporins
- monobactums
- carbapenems
All possess a beta lactam ring
Differ in the side chain attached to this
nucleus
Target site is peptidoglycan which is present
only in bacteria
side effects of penicillin
Relatively safe
Hypersensitivity rash
Avoid amoxicillin in patients with infectious
mononucleosis -‘glandular fever’ - EBV
Anaphylaxis rare (0.004%) but can be fatal
Excreted by the kidneys: reduce dose in renal
failure
Diarrhoea – not uncommon
cefalsporins
Mostly stable to staphylococcal betalactamase
Much «_space;than 10% cross allergy with penicillins
So diverse – defy rigid classification
Consider: oral cefalexin (UTI) AND iv cefuroxime, iv ceftriaxone/cefotaxime (sepsis, meningitis) iv ceftazidime (pseudomonas) Improved ßlactamase stability: cefalexin < cefotaxime < ceftazidime
glycopeptides
e.g vancomycin, teicoplanin
Inhibit cell wall synthesis by binding to terminal
D-ala-D-ala of the peptide chain and prevents
incorporation of new sub units to the growing cell
wall.
For Gram positives not Gram negatives
Important in MRSA infection
Some nephro and ototoxicicity - check serum
levels
IV for systemic infection (but oral for C. difficile
infection- not absorbed)
protein synthesis inhibitors
Aminoglycosides e.g gentamicin Tetracyclines Macrolides (erythromycin, clarithromycin) Chloramphenicol (rarely used in the UK) Lincosamides Oxazolidones Fusidic acid
aminoglycosides
Low therapeutic index Very good v.s Gram negatives eg E. coli, Pseudomonas aeruginosa (…and Mycobacteria..) Anti-Staphylococcal activity Not active against anaerobes Not absorbed orally Ototoxic and nephrotoxic Monitor serum levels during therapy
tetracyclines
Bacteriostatic Broad spectrum Intracellular bacteria e.g. chlamydia May cause diarrhoea, nausea Teeth discolouration, avoid in children, pregnant & lactating women
macrolides
Erythromycin; clarithromycin, azithromycin
Usually bacteriostatic, bactericidal in high
concentrations
Mainly narrow spectrum (mainly Gram positives
e.g. S.aureus, Group A streptococci)
Suitable for penicillin allergic patients
Intracellular bacteria e.g Legionella sp, chlamydia
Erythromycin cheap
side effects of macrolides
Gastrointestinal upset common – less with
newer agents
Thrombophlebitis when given intravenously
‘Newer’ macrolides have broader spectrum
- clarithromycin and azithromycin
protein inhibitor synthesis inhibitors (cont)
Lincosamides: clindamycin
Gram positives esp Group A strep, anaerobes;
bacteriostatic, oral/iv; cheap, diarrhoea/colitis
Oxazolidone: ‘Linezolid’:
Bacteriostatic; gram positives only;
VRE/MRSA, may cause pancytopaenia, neuritis
& neuropathy, oral/iv, costly!
inhibitors of nucleic acid synthesis
1) Synthesis of tetrahydrofolic acid
(THFA)
2) Synthesis of RNA
3) Synthesis of DNA
1) THFA inhibitors
Sulphonamides - structural analogues of
PABA (para-aminobenzoic acid)
Trimothoprim – ‘folate’ antagonist – binds
dihydrofolate reductase – selectively toxic
to bacteria
Humans, unlike bacteria do not make folic
acid, must take in diet
inhibitors of RNA synthesis
rifampicin
Inhibits RNA polymerase enzyme
Used as part of combination treatment for
Mycobacterium tuberculosis + M. leprae.
Also for severe Staphylococcus aureus infections
Always in combination as resistance develops
easily on monotherapy
Significant drug interactions (hepatic enzyme
inducer); colours secretions;
inactivates oral contraceptive pill
inhibitors of dna synthesis - 1
QUINOLONES
Useful– mainly: multi R GNB; UTI; typhoid
Synthetic, well absorbed. IV/PO.
Act by inhibiting DNA gyrase (Gram negatives)
and topoisomerase IV (Gram positives)
Bactericidal
DNA synthesis inhibitors - 2
Fluoroquinlones - Ciprofloxacin
- Broad-spectrum
- Low MICs
- Rapidly bactericidal
- Resistance can be slow to develop
quinolones side effects
Neurotoxicity, confusion, fits
Cartilage defects. Not used in pregnant
women and children
Photosensitivity
Association with C. difficile infection
(Previously in lime-light for anthrax prophylaxis/ treatment;
now 1st choice for meningococcal
contacts prophylaxis)
main route of administration
Parenteral (intravenous/intra muscular) Intraperitoneal Oral Rectal Topical often discouraged
what are the factors that promote the success of antibiotic resistance
1. Antibiotic Usage • Too much antibiotic • Too little antibiotic 2. Effective Genetic Mobility • Plasmid Carriage • Transposons •Integrons 3. Efficient Resistance Mechanism • Bacterial factors
location of resistance genes
Chromosome
Plasmid
Transposon
Integron
transposon
“Jumping genes”
Go between plasmid & chromosome
Unable to replicate independently
integron
Genetic element Usually resides on transposon Able to ‘poach’ resistant genes ie extracts DNA segments and inserts into other DNA segments
main mechanisms of resistance
1) Target site alteration
2) Reduced access (efflux or impermeability)
3) Drug inactivation
4) Metabolic bypass
what antibiotics are we trying to avoid
Broad spectrum antibiotics Ciprofloxacin and other quinolones Cephalosporins Clindamycin Co-amoxiclav
viral infectivity cycle - 1
Attachment/Adsorption
Penetration
Uncoating
viral activity cycle - 2
Transcription
Synthesis of nucleic acid & proteins
Assembly
Release by rupture or budding – often results in cell death
antivirals
Definition – inhibit viral replication
(most narrow spectrum, N.B. selective toxicity)
Virustatic – do not stop replication completely – this is done by immune system
Uses -Therapeutic/ Prophylactic
Population at risk, Immunocompromised (e.g. Cancer, Transplant & HIV)
Pregnant women, neonates
viral DNA/RNA synthesis inhibitors
aciclovir (HSV & Herpes) zidovudine (HIV)
viral protein synthesis inhibitors
ritonavir (HIV)
boceprevir (HCV)
release of viral particles inhibition
oseltamavir (influenza)
fungi - general
the eukaryotic fungal cell is more difficult to selectively inhibit than the prokaryotic bacterial cell.
Fungi have sterols in their cell membrane
-usual drug target site
classes of antifungals
Polyenes
Azole group (Imidazole & Triazoles)
Echinocandins
Others
principles of TB therapy
Always combination Rx (treatment)
Drugs “first” and “second” line
Choice of number and types of drugs based on history, previous treatment, source, geographical location…
Rx of TB undertaken by specialists only
(now increasing PCR diagnosis on specimens)
causes of lung cancer
• SMOKING (>95%) – Passive smoking (effects difficult to quantify) • Occupational exposures – Uranium mining – Asbestos exposure • Environmental exposures – Radon gas • Genetic – Li-Fraumeni Sydrome (mutated p53 gene)
types of lung cancer
• Squamous Carcinoma (30-40% and decreasing) • Adenocarcinoma (40-50% and increasing) • Small cell carcinoma (20%) • Others (5%) – Carcinoid tumours
squamous carcinoma
- the tumour cells are showing squamous differentiation
- keratin production or ‘prickles
- common finding in smokers
- reversible
adenocarcinoma
Evidence of a glandular growth pattern or mucin production
• Central tumours may arise in a similar
manner to squamous carcinoma but premalignant states not really recognised
• Peripheral tumours now believed to arise
through a sequence of step-wise changes.
small cell (undifferentiated) carcinoma
Very poorly differentiated carcinoma showing variable evidence of
neuroendocrine differentiation
aggressive tumour
carcinoid / neuroendocrine
Typical (Classical) carcinoid
– < 2 mitoses per 2mm2
– No necrosis
• Atypical carcinoid
– > 2 but < 10 mitoses per 2mm2
– Focal necrosis (may be very focal commedo like)
– > 10 mitoses per 2mm2 with usually extensive necrosis
then classified with LCNEC
symptoms and signs of lung cancer
• Cough • Dyspnoea • Haemoptysis • Weight loss • Chest/shoulder pain • Hoarseness • Fatigue • Slow to clear pneumonia • Finger clubbing • Cervical lymphadenopathy • Liver, bone, brain metastases • Pleural effusion
initial investigations - lung cancer
• Radiology – Chest x-ray – CT scan • Bloods – High Ca – Abnormal liver function tests – Low serum Na
immunohistochemistry - lung cancers
Squamous markers • CK5, CK14, p63, 34βE12 – Adenocarcinoma • CK7, TTF1 (c. 70-80% of primary lung tumours)
behaviour of lung cancers
• Intrapulmonary growth – Obstructive pneumonia – Lymphangitis carcinomatosis • Invasion of adjacent structures – Pleura (with associated effusion) – Chest wall – Mediastinum (SVC, phrenic nerve, recurrant laryngeal nerve, atrium, aorta, oesophagus) – Diaphragm
staging lung cancer
Staging is assessing the extent of tumour growth
and spread
• Allows patients to be grouped together for
treatment schedules/trials
• Predictor of prognosis
• TNM system
– ‘T’ a measure of the growth of the primary tumour
– ‘N’ indication of the extent of local nodal disease
– ‘M’ presence or absence of distant metastases
treatment for lung cancer
Best supportive / palliative care • Chemotherapy • Radiotherapy • Surgery – around 15% – Advanced disease at presentation – Co-morbities eg emphysema, ischaemic heart disease
lung function after lung cancer operations
Lobectomy – early deficit with later recovery & little permanent loss in PFT (≤10%) & no decrease in exercise capacity.
Pneumonectomy – early permanent deficit 33% loss in PFT and 20% decrease in exercise capacity
anatomical shunts
A small amount of arterial blood doesn’t come from the lung (Thebesian veins)
A small amount of blood goes through without seeing gas (bronchial circulation)
Physiological shunts (decreaseV) and alveolar dead space (decreaseQ)
Not all lung units have the same ratio of ventilation (V) to blood flow (Q)
V/Q mismatch
what decreases the partial pressure of O2 in blood
Hypoventilation so less oxygen to enter the blood
Hypoventilation allows less air to enter and leave the alveoli and have decreased alveolar oxygen
Decreased environmental oxygen e.g. altitude
what can increase partial pressure of oxygen
Hyperventilation
Administration of oxygen
increase in available PO2 in healthy state
Slight increase in haemoglobin saturation
Little change in oxygen content
At a normal PO2, blood carries nearly as much oxygen as it possibly can
Therefore increasing the PO2 has very little effect on the oxygen content
However in disease oxygen therapy is a key intervention
ventilation to perfusion ratio
V/Q
If ventilation = perfusion then will get perfect gas exchange
In the lung naturally have V/Q mismatch with less blood and air going to the top of the lung
normal V/Q mismatch
Less airflow and blood flow at the top of the lung but V>Q = increased V/Q
Middle of lung V/Q normal
Bottom of lung more ventilation and more blood flow but V
increased V/Q ratio
Lots of ventilation to alveoli, not much blood
Alveoli and blood reach an equilibrium which is closer to air
PO2 is therefore higher
(and PCO2 is lower)
decreased V/Q ratio
Less ventilation to alveoli, lots of blood
Alveoli and blood reach an equilibrium which is closer to venous blood
PO2 is therefore lower (and PCO2 is higher)
physiological dead space
Anatomical dead space represents the conducting airways where no gas exchange takes place
Alveolar dead space represents areas of insufficient blood supply for gas exchange and is practically non-existent in healthy young but appears with age and disease
Physiological dead space = anatomical dead space + alveolar dead space
quantifying V/Q mismatch
Calculate the expected alveolar PO2 (PAO2) using the alveolar gas equation
Compare with the measured arterial PO2 (PaO2)
If PAO2 = PaO2 then no mismatch
quantifying A-a Gradient
Tells us the difference between alveolar and arterial oxygen level
Can help to diagnose the cause of hypoxaemia
High A-a gradient
Problem with gas diffusion
V/Q mismatch
Right to left shunt
hypoventilation and CO2
During normal ventilation CO2 diffuses out of blood into alveolus following a partial pressure gradient
CO2 is mostly dissolved in blood rather than bound to haemoglobin
If there is lower ventilation then CO2 accumulates in the alveolar space meaning less can be removed from the blood
arterial blood gases - WHAT IS MEASURED
- PaO2
- PaCO2
- HCO3-
- H+
PaO2 low, CO2 normal
Type 1 respiratory failure
Probably has V/Q mismatch
PaO2 low, CO2 high
Type 2 respiratory failure
Patient has ventilatory failure
(May well have V/Q mismatch too
failure of ventilatory pump
Won’t breathe: control failure
Brain failure to command e.g. drug overdose
Sometimes in COPD
Can’t breathe: broken peripheral mechanism
Nerves not working e.g. phrenic nerve cut
Muscles not working e.g. muscular dystrophy
Chest can’t move e.g. severe scoliosis
Gas can’t get in and out e.g. asthma/COPD
type 2 respiratory failure
Decrease in PO2 Increase in PCO2 Common causes in hospital: Severe COPD (can be acute or chronic) Acute Severe Asthma Pulmonary Oedema in acute Left Ventricular failure Due to hypoventilation as main feature
How do we treat type 2 respiratory failure
Give oxygen
Controlled in COPD patients with chronic respiratory failure
Treat the underlying cause to reverse hypoventilation e.g. bronchodilators for acute asthma or opiate antagonists for overdoses
Support ventilation
Non-invasive ventilation
Invasive ventilation
what causes V/Q mismatch
- Most lung diseases effecting the airways and parenchyma
- Lung infection such as pneumonia
- Bronchial narrowing such as asthma and COPD (although they can also progress to type 2 resp failure)
- Interstitial lung disease
- Acute lung injury
V/Q mismatch in pneumonia
Creates a shunt leading to low PO2 because blood does not come into contact with adequate O2
what happens to arterial CO2 in V/Q mismatch
- Blood leaving areas of low V/Q ratio has
- Low PaO2
- High PaCO2
- High PaCO2 stimulates ventilation
- ‘Extra’ ventilation goes to areas of normal lung and areas with high V/Q ratio so get blood with low CO2
- Blood from both areas mixes so overall CO2 is normal
what happens to to arterial O2 in V/Q mismatch
- Blood leaving areas of low V/Q ratio has
- Low PaO2
- High PaCO2
- High PaCO2 stimulates ventilation
- ‘Extra’ ventilation goes to areas of normal lung and areas with high V/Q ratio
- But extra ventilation can’t push O2 content much higher than normal
- Blood from both areas mixes but cannot overcome the low oxygen level
treatment of pulmonary embolism
Oxygen in acute episode
Anticoagulation to stop further clot propagation
Thrombolysis in some cases where circulatory compromise
asthma and respiratory failure
Hypoxaemia suggests significant asthma attack
Bronchospasm and mucous plugging causes ventilation defects and V/Q miss match
Type 2 resp failure develops when severe bronchospasm causes hypoventilation of alveoli or exhaustion
The patient needs oxygen to survive
Invasive ventilation may be required
COPD and respiratory failure
COPD is a mixture of chronic airways inflammation and narrowing and emphysema
Problems with V/Q mismatch and hypoventilation
May present acutely with respiratory failure type 1 or type 2
May have chronic type 2 respiratory failure in advanced disease
Treat respiratory failure with oxygen but with caution in chronic type 2 respiratory failure
oxygen therapy masks
Variable performance
Cheap and cheerful
Exact inspired O2 concentration not known
Fixed function
Constant, known inspired concentration
Reservoir mask
High inspired concentration of O2
how do we treat respiratory failure
- Give oxygen
- This is a short term life saving measure
- The fundamental problem is inadequate gas exchange
- Improve gas exchange: treat underlying cause
- In some cases mechanical ventilation is required
why measure blood gases
To assess very sick patients
To diagnose respiratory failure
To diagnose metabolic problems
quantifying O2 carriage
1 - Haemoglobin saturation
Because it’s very easy to do!
Assuming Hb is normal, it’s an accurate reflection of oxygen content
2- Arterial blood gases
More complicated and invasive
PaO2 reflects haemoglobin saturation but is a measure of the partial pressure of O2 in the blood
how to measure haemoglobin saturation
- Oxygenated haemoglobin is RED
- Deoxygenated haemoglobin in BLUE
- Using absorption spectroscopy, it is possible to estimate the degree of saturation of haemoglobin
- SpO2, pulse oximetry
how to measure ABG
Single arterial puncture technique
- Radial artery
- Femoral artery
- Brachial artery
Measurement from in-dwelling arterial catheter or A-line
- Only really an option in HDU/ITU
what does blood gas measure
- PaO2
- PaCO2
- Hydrogen ion/pH
- Bicarbonate
- Some analysers may also measure electrolytes and Hb
- Other forms of haemoglobin:
- Carboxyhaemoglobin
normal blood gas values
H+ 36-44 nmol/l
PO2 12-15 kPa
PCO2 4.4-6.1
HCO3 21-27.5
BE +2 to -2 mmol/l
understanding O2 kPa
Partial pressure of oxygen in the air is 21 kPa
The total pressure in the atmosphere is 100 kPa
21% of the air is oxygen, therefore 21% of the total pressure is the partial pressure of oxygen
This depends on environment
acidosis
H+ is increased by:
An increase in pCO2 (respiratory acidosis)
An increase in acid production or decrease in excretion (metabolic acidosis)
acute vs chronic type 2 respiratory failure
Acute hypoventilation e.g. due to opiate toxicity leads to hypoxia, hypercapnia and acidosis
Chronic hypoventilation e.g. neuromuscular disease or severe COPD leads to hypoxia and hypercapnia but may not have acidosis due to compensation
- increased bicarbonate retention in kidney
respiratory alkalosis
Not usually associated with respiratory failure Caused by hyperventilation Have low PCO2 and low H+ PO2 14 PCO2 2.2 H+ 32 HCO3 25
metabolic problems
Excess acid production by the body e.g. lactic acidosis or diabetic ketoacidosis
Kussmal breathing is a classical clinical sign of acidosis as a compensatory mechanism to increase CO2 removal from the blood
Full compensation is difficult: need to treat the underlying cause of increased acid load e.g. treatment of DKA
interpreting bicarbonate
Actual bicarbonate:
- Calculated with actual H+ and pCO2 values
Standard bicarbonate:
- Calculated with actual H+ and a pCO2 of 5.3kPa (normal pCO2)
- Standard bicarbonate is therefore only influenced by metabolic effects
base excess
The amount of base needed to be removed from a litre of blood at a normal pCO2 in order to bring the H+ back to normal
Sounds complicated but it’s not:
- It is calculated with a normal CO2, so it only looks at the metabolic component
- Normal value is zero (-2 to 2 mmol/l)
- A big negative value indicates a metabolic acidosis
- A positive value seen in compensated respiratory acidosis
anion gap
The anion gapis the difference between primary measured cations (Na+and K+) and the primary measuredanions (Cl-and HCO3-) in serum.
causes of respiratory acidaemia
- impaired gas exchange‐- Hyperventilation
- Lung disease, COPD
‐Drugs (respiratory depression)
‐Muscle paralysis
causes of respiratory alkalaemia
hyperventilation from -
‐Salicylate poisoning (aspirin)
‐Hysteria, anxiety
‐Cerebral diseases such as viral infection/head injury
causes of metabolic acidaemia
- acidic metabolic products
- loss of HCO3
- chronic diarrhea (bile salts)
- increase buffering demand (eg keto/lactic acidaemia)
- acid indigestion
causes of metabolic alkalaemia
- bicarbonate indigestion
‐ Severe vomiting (HCl loss)
common causes of metabolic acidaemia (anion gap)
methanol ethylene glycol salicylate lactic acidaemia alcoholic ketoacidosis renal failure diabetic ketoacidosis
principle buffers in plasma
phosphate
- buffers intracellular fluid
- important urinary buffer
protein
- present in large amounts
- buffers intracellular fluid & plasma
- haemoglobin buffers RBC
bicarbonate
- primary extracellular fluid buffer
ammonia
-allows excretion of H+ as NH4 in acidaemia
acute bronchitis
Inflammation of bronchi • Often viral • May be bacterial e.g. H influenzae • May also involve larynx and trachea - laryngotracheobronchitis • Acute exacerbations of ‘chronic bronchitis’ are common
bronchiolitis
- Inflammation of bronchioles
- A feature of chronic bronchitis
- Primary bronchiolitis
- Usually in children
- Respiratory syncytial virus (RSV)
- Tachypnoea and dyspnoea
- Rare types
- Follicular bronchiolitis
- Bronchiolitis obliterans
diffuse obstructive airway disease
• Reversible and intermittent OR Irreversible and persistent • Centred on bronchi and bronchioles • Diffuse disease as many airways involved • Pulmonary function tests ‘obstructive’ • Reduced vital capacity (VC) • Reduced FEV1 / FVC ratio • Reduced peak expiratory flow rate
examples of diffuse obstructive airway disease
- Several clinico-pathological entities
- Chronic bronchitis
- Emphysema
- Asthma
- (Bronchiectasis)
• Chronic obstructive pulmonary disease (COPD)
• Spectrum of co-existence of chronic bronchitis and
emphysema
chronic bronchitis
Cough and sputum for 3 months in 2 consecutive
years
• Aetiology - pollution, smoking
• Clinical
• Middle-aged heavy smokers
• Recurrent low-grade bronchial infections (exacerbations)
• H. influenzae, S. pneumoniae, viruses
• Airway obstruction may be partially reversible
progression of chronic bronhcitis - final outcome
• Hypercapnia • Hypoxia • Pulmonary hypertension • ‘Cor pulmonale’ - right ventricular failure
• ‘Blue bloater’
pathology of chronic bronchitis
- Respiratory bronchiolitis (<2mm diameter)
- Can lead to centrilobular emphysema
- Mucus hypersecretion
- Mucous gland hypertrophy
- Chronic bronchial inflammation
- Squamous metaplasia, increased risk of malignancy
emphysema
• Irreversible dilatation of alveolar spaces with
destruction of walls
• Associated with loss of surface area for gas
exchange
centrilobular emphysema
Strongly associated with smoking
• Seen in some with pneumoconiosis, particularly
coal-workers
• Most commonly in upper lobes
• Respiratory bronchiolitis often present
panlobular emphysema
• Usually lower lobes
• Lungs overdistended
• Associated with alpha-1-antitrypsin deficiency
• Markedly accelerated in smokers with this
disorder
other forms of emphysema
- Paraseptal
- Distension adjacent to pleural surfaces
- May be associated with scarring
- Irregular
- Associated with scarring
- Overlap with paraseptal emphysema
- Others
- Bullous: distended areas >10mm
- Interstitial
clinical features of emphysema
• Hyperventilation • Normal pO2, pCO2 • ‘Pink puffer’ • Weight loss • Right ventricular failure • Often co-existing chronic bronchitis, in which case clinical features are mixed
asthma
Reversible wheezy dyspnoea’ • Increased irritability of the bronchial tree with paroxysmal airway narrowing • Five aetiological categories • Atopic • Non-atopic • Aspirin-induced • Occupational • Allergic bronchopulmonary aspergillosis (ABPA)
atopic asthma
Associated with allergy
• Triggered by a variety of factors
• Dust, pollen, house dust mite etc etc
• Often associated with eczema and hay fever
• Bronchoconstriction mediated by a type I
hypersensitivity reaction
non-atopic asthma
- Associated with recurrent infections
- Not immunologically mediated
- Skin testing negative
allergic bronchopulmonary aspergillosis
Specific allergic response to the spores of Aspergillus
fumigatus
• Mixed type I and type III hypersensitivity reaction
• Mucus plugs common
• Associated with bronchiectasis
• Not to be confused with an aspergilloma, which is a
fungal ball, usually colonising a pre-existing cavity in
the lung (often tuberculous)
bronchiectasis - 2
• Permanent dilatation of bronchi and bronchioles
• Due to a combination of obstruction and inflammation
(usually infection)
• May be localised or diffuse, depending on cause
• Historically seen in patients with pulmonary
tuberculosis involving hilar lymph nodes
• Classically associated with childhood infections,
particularly measles and whooping cough
• Diffuse bronchiectasis seen in patients with cystic
fibrosis
clinical features of bronchiectasis
• Chronic cough productive of copious sputum • Finger clubbing • Complications • Spread of infection • Pneumonia, Empyema, Septicaemia, Meningitis, Metastatic abscesses e.g. brain • Amyloidosis • Respiratory failure
the air travels down
Nasal Cavity
Pharynx
Larynx
Trachea
Bronchi
Bronchioles
Alveoli
features of the nasal cavity
Conchae = turbinate
Meatus = passage or opening
paranasal sinuses
frontal
ethmoidal
maxillary
sphenoidal
drain into nasal cavity
nasal cavity- communicating structures
Pharyngotympanic tube– connects nasal cavity to the middle ear
Nasolacrimal duct (tear duct) – connects lacrimal sac to nasal cavity
the pharynx
nasopharynx
oropharynx
laryngopharynx
soft palate “flutter valve”
innervation of the pharynx
vagus nerve [X]
glossopharyngeal nerve [IX]
the larynx - structure
Voice Box
Cartilaginous structures
- hyaline cartilage
- elastic fibrocartilage
epiglottis
Closes over the entrance to the larynx to stop food/ liquid entering during swallowing
histology of respiratory system
Most of the upper respiratory tract is covered in pseudostratified columnar ciliated epithelium (“respiratory epithelium”)
Goblet cells (G) – produce mucus to trap foreign particles
Cilia (C) - beat to transport mucus out of the respiratory system
bronchiole histology
<1mm lumen Pseudostratified ciliated columnar epithelium Ciliated columnar epithelium NO glands NO cartilage Smooth muscle (M)
what is an obstructive disorder
- narrowing of airway
- reduced inflow of gas
- reduced inflation of alveoli
factors affecting airway internal diameter
- Increased mucus production
- Anatomical features
- Autonomic and Non-Adrenergic/Non-Cholinergic (NANC) systems
- Inflammation
autonomic and NANC Nervous systems
parasympathetic nerve (vagus)
- acetyl choline
- muscarinic receptors
- constriction
the circulation
- B2 adrenergic receptors
- bronchodilation
cystic fibrosis
- autosomal recessive
- mutation in CTFR gene - encodes it protein, a chloride and bicarbonate ion channel present on cell membrane
- multi-system disease
- median survival 47 yrs
how to measure obstruction
peak flow
spirometry
lung volumes & flow
airway resistance and flow calculation (calculates peak expiratory flow)
(upstream pressure - downstream pressure) / resistance
volume of gas per unit of time
PEF in asthmatics
morning dips
FEV1 & FVC
FEV1 - How much can the patient exhale in a given time, e.g. 1 second
FVC - How much they can exhale altogether
Factors to consider when looking at FEV1:FVC ratio
We compare to predicted values based on age, sex and height
Predicted values are based on population of healthy individuals
if <0.7 suggests obstructive airway pathology
Global Lung Initiative (GLI) lung function prediction
Global initiative set up in 2008 to standardize the predicted values for spirometry
Now adopted as gold standard in many countries
Online tool for data interpretation
effect of mild/moderate obstruction on lung volumes
TLC remains in normal range
- airway narrowing and collapse leads to gas trapping
- RV increased above normal range
- RV/TLC ratio increased above normal
effects of severe airway obstruction on lung volumes
TLC increased above normal range due to destruction of lung tissue (emphysema)
VC decreased
- extensive airway narrowing and collapse leading to gas trapping
- RV substantially increased above normal range
- RV/TLC ratio increased
reversibility of spirometry
Used as a diagnostic test in Asthma e.g. following bronchodilator
Asthma reversible vs. COPD fixed airways obstruction
Can also use bronchial challenge agents (histamine) to induce bronchospasm and obstructive spirometry
what is a restrictive disorder
A disorder in which prevents normal expansion of the lungs
what causes lung restriction
Extra-pulmonary disease
i.e. visceral pleura, pleural space, chest wall including parietal pleura, bones, muscles, nerves
Intra-pulmonary disease
i.e. alveolar spaces
extra-pulmonary restrictions
- Integrity of nerves to respiratory muscles
e. g. high cervical dislocation - Impaired neuromuscular junctions
e. g. myasthenia gravis - Impaired muscles
e. g. muscular dystrophy - Pleural thickening
e. g. asbestos exposure - Skeletal abnormalities
e. g. scoliosis
intra-pulmonary restrictions
diseases causing increased fibrous tissue in lung
- silicosis in stonemason
- asbestosis
- drug-induced lung fibrosis
- coal-worker pneumoconiosis
- rheumatoid-lung
- bird-fanciers lung
- idiopathic pulmonary fibrosis
how do fibrotic lung diseases cause restrictive disease
- Inflation pressure
- Compliance
- Elastic recoil
elastic recoil pressure =
alveolar pressure minus pleural pressure
pulmonary compliance
the ability of the lungs to stretch during a change in volume relative to an applied change in pressure (‘stretchability’)
relationship between inflation pressure, compliance and elastic recoil
A lower compliance means greater inflation pressure required to inflate which means higher elastic recoil
effects of a decreased compliance on inflation
increased fibrous tissue (more rigid)
decreased compliance (requires high pressure to inflate)
Increased elastic recoil (deflates easily)
what casues increased compliance
Associated with an OBSTRUCTIVE defect, particularly emphysema
effects of increased compliance on deflation
decreased elastic tissue (more floppy) increased compliance (inflates at low pressures) decreased elastic recoil (difficult to deflate)
alveolar features making them different from balloons
- Alveoli are moist
2. Alveoli are of different sizes
alveoli being different size - effect
air moves from HIGH pressure area to LOW pressure area
SMALLER alveolus empties into LARGER alveolus
There is INSTABILITY of adjacent alveoli
surfactant
produced by alveolar Type II cells
composed of lipids (90%, mainly phospholipids) and proteins (10%)
reduces surface tension
well-expanded alveoli (inspiration) - surfactant
Surfactant spread evenly over alveolar surface but molecules spread out
Surfactant has little effect on surface tension (sT)
deflated alveoli (expiration) - surfactant
Tightly packed surfactant molecules
Some surfactant molecules extruded from the surface
Surfactant significantly reduces surface tension (T) with accompanying lower pressure (P)
pressure equation
P = (2 * sT) / radius
respiratory distress syndrome of the newborn
caused by lack of surfactant
Surfactant first produced 210 days c.f. full term = 280 days (40 weeks)
low compliance
high inflation pressures
rapid shallow breathing - fatigue
hypoxaemia
impaired surfactant contributes to what resp. disorders
Adult respiratory distress syndrome (ARDS) Pneumonia Idiopathic pulmonary fibrosis Lung transplant ………etc
spirometry and lung volumes in restriction
decreased….
spirometry
- FEV1
- FVC
Helium dilution
- total lung capacity
- vital capacity
- residual volume
gas transfer measurement
Gas transfer is a measure of the diffusing capacity of the lung.
It requires a measurement of GAS EXCHANGE and ALVEOLAR VOLUME
measuring gas exchange
use CO - carbon monoxide
Rapidly taken up by haemoglobin with very high affinity
Not produced by the body
Non-toxic
Easy to measure
measuring alveolar volume
use He - Helium
NOT TAKEN UP by haemoglobin
Not produced by the body
Non-toxic
Easy to measure
what can you calculate using single breath method - CO
TLCO (mmol/min/kPa)
- total gas exchange capacity
VA
- alveolar volume
KCO
- efficiency of gas transfer per unit of lung
TLCO and KCO - extra-pulmonary restrictive
TLCO low
-lungs are smaller
KCO high
-alveoli are normal and tightly packed with blood vessels